India is witnessing a mild surge in COVID-19 cases as of May 22, 2025, with 257 active cases reported, primarily in Kerala, Maharashtra, Tamil Nadu, and Gujarat. Driven by the JN.1 Omicron subvariant and its descendants LF.7 and NB.1.8, this uptick, reported by the Ministry of Health, raises questions about waning vaccine immunity. The surge, linked to declining antibodies from vaccinations and prior infections, has prompted experts to urge masking and boosters to curb the spread.
In This Article:
The Surge and Vaccine Immunity
India’s 257 active cases, though mild, reflect a regional trend, with Kerala leading at 95 cases and Mumbai reporting 95 cases in May alone. The JN.1 variant, a highly transmissible descendant of BA.2.86 (Pirola), evades immunity due to a spike protein mutation, as per WHO. Experts note that India’s vaccination campaign, with 1.7 billion doses (70% single-dose, 58.8% fully vaccinated), relies on Covaxin and Covishield, less effective against JN.1. mRNA vaccines like Gemcovac-19, better suited for new variants, remain scarce. A PLoS Pathogens study suggests memory T and B cells from prior infections or vaccines still reduce severity, but waning antibodies increase reinfection risks.
Public and Expert Response
Health officials maintain the situation is “under control,” with no severe cases or deaths linked directly to JN.1, per PTI. However, celebrities like Shilpa Shirodkar testing positive have amplified public concern, with X posts urging, “Mask up, COVID’s back!” Dr. Jatin Ahuja from Apollo Hospitals, Delhi, emphasizes precautions like hand hygiene and avoiding crowded spaces, especially for the elderly, immunocompromised, and those with comorbidities like diabetes.
Challenges and Solutions
The surge, mirroring spikes in Singapore (14,200 cases) and Hong Kong, underscores the need for updated boosters. India’s Integrated Disease Surveillance Programme monitors cases, but low booster uptake—only 22.86 crore precaution doses—hampers efforts. Experts advocate for mRNA vaccine access and genomic surveillance to track variants like XEC. With hospitalizations low (133 daily in Singapore), panic is unwarranted, but vigilance is key.
Looking Ahead
India’s hybrid immunity from high natural infection rates offers some protection, but periodic surges are likely as COVID becomes endemic. Strengthening booster campaigns and public awareness can mitigate risks, ensuring this mild wave doesn’t escalate.
-By Manoj H